| Population 2015 |
189 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
44 |
(9.3–110) |
23 |
(4.9–56) |
| Mortality (HIV+TB only) |
1.6 |
(1.1–2.1) |
0.83 |
(0.6–1.1) |
| Incidence (includes HIV+TB) |
510 |
(330–729) |
270 |
(175–386) |
| Incidence (HIV+TB only) |
8.8 |
(5.4–13) |
4.6 |
(2.8–6.9) |
| Incidence (MDR/RR-TB)** |
26 |
(16–36) |
14 |
(8.5–19) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
25 |
(12–37) |
231 |
(141–320) |
255 |
(153–357) |
| Males |
21 |
(13–29) |
234 |
(163–305) |
255 |
(175–335) |
| Total |
46 |
(30–61) |
465 |
(357–573) |
510 |
(330–729) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
331 809 |
| Total new and relapse |
323 856 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
4% |
| - % pulmonary |
81% |
| - % bacteriologically confirmed among pulmonary |
51% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
63% (44–98) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.09 (0.02–0.23) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
59 |
<1% |
| - on antiretroviral therapy |
59 |
100% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
14 000
(11 000–16 000) |
| Estimated % of TB cases with MDR/RR-TB |
4.2% (3.2–5.3) |
16% (15–17) |
|
| % notified tested for rifampicin resistance |
1% |
84% |
23 078 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
2 292 |
| Laboratory-confirmed cases |
MDR/RR-TB: 3 059, XDR-TB: 99 |
| Patients started on treatment **** |
MDR/RR-TB: 2 553, XDR-TB: 68 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
93% |
308 327 |
| Previously treated cases, excluding relapse, registered in 2014 |
82% |
8 005 |
| HIV-positive TB cases, all types, registered in 2014 |
|
|
| MDR/RR-TB cases started on second-line treatment in 2013 |
69% |
1 484 |
| XDR-TB cases started on second-line treatment in 2013 |
30% |
64 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
62 |
| Funding source: <1% domestic, 65% international, 35% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |